Glycostem is a life science company, opening new horizons in allogeneic NK-cell-based immunotherapy, thanks in large part to its cutting-edge platform technology. In recent years, Glycostem has enabled a closed-system cell-culture process for the largescale expansion of CD34+ hematopoietic stem and progenitor cells, derived mainly from umbilical cord blood.
By leveraging its unique and versatile production-platform technology, Glycostem has developed highly pure and active cancer-fighting cell therapy products that are safe and effective for allogeneic transplantation in patients with hematological cancers and solid tumors.
“At Glycostem, we believe that natural killer cells will become the new star in the domain of cellular immunotherapy,” said the company’s chairman and CEO, Troels Jordansen. “By developing a suite of innovative natural killer cell products, Glycostem is setting the stage to make a considerable impact on the future treatment of cancer.”
Area of work
Oncology, Drug discovery, Drug development, Stem cell therapy , Natural Killer Cells
Highly motivated students looking for internship opportunities can write to us with your CV to email@example.com.